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4. ABSTRACT 
Objective: Maternal obesity is characterized by systemic low-grade inflammation and oxidative stress 
(OxS) with the contribution of fetal sex dimorphism. We recently described increased mitochondrial 
content (mtDNA) in placentas of obese pregnancies. Here we quantify mtDNA and hepcidin as indexes 
of OxS and systemic inflammation in the obese maternal circulation. 
Methods: fourty-one pregnant women were enrolled at elective cesarean section: sixteen were 
normal-weight [NW] and twenty-five were obese (OB). Obese women were further classified 
according to the presence/absence of Maternal Gestational Diabetes (GDM); [OB/GDM(-)]: n=15, 
[OB/GDM(+)]: n=10. mtDNA and hepcidin were evaluated in blood (Real-Time-PCR) and plasma 
(ELISA). 
Results: mtDNA and hepcidin levels were significantly increased in OB/GDM(-) vs NW, significantly 
correlating with pre-gestational BMI. Male/female (M/F) ratio was equal in study groups, and overall 
F-carrying pregnancies showed significantly higher mtDNA and hepcidin levels than M-pregnancies 
both in obese and normal weight mothers. 
Conclusions: Our results indicate a potential compensatory mechanism to increased obesity-related 
OxS and inflammation, indicated by the higher hepcidin levels found in obese mothers. Increased 
placental mitochondrial biogenesis, due to lipotoxic environment, may account for the greater mtDNA 
amount released in maternal circulation. This increase is namely related to F-carrying pregnancies 
suggesting a gender specific placental response. 
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6. MAIN TEXT 
INTRODUCTION 
Maternal obesity (MO) is expanding exponentially worldwide to almost epidemic proportions. It 
represents a significant risk factor for several pregnancy pathologies, leading to adverse pregnancy 
and fetal/neonatal outcomes [1], and may also affect offspring health in later life [2]. In obese 
pregnancies, systemic dysfunctions together with an altered intrauterine environment may contribute 
to these increased risks, with the possible involvement of placental/fetal sex dimorphism [3-4]. 
One of the most frequent complications occurring in pregnancies of obese women is Gestational 
Diabetes Mellitus (GDM). GDM affects approximately 7% of pregnancies, with 1.3-3.8 fold increased 
frequency in obese women [5]. GDM is a pregnancy complication characterized by maternal insulin 
resistance and systemic inflammation. Moreover, the placenta presents several alterations, leading to 
defective oxygen and increased nutrients availability for the fetus [6-7]. 
MO is characterized by energy imbalance of calories intake/consumption and by excessive macro- 
opposite to few micro-nutrients intake [8]. This results in high levels of intracellular fatty acids leading 
to increased intracellular inflammation and oxidative stress (OxS) [9]. 
Obesity-related inflammation and OxS possibly alter mitochondria structure and function. 
Mitochondria (mt) are a source of Reactive Oxygen Species (ROS), at the same time they are 
susceptible to ROS-mediated actions leading to DNA/protein damage and cellular senescence. 
Alterations of mt content and function have been reported in maternal blood and placentas of 
pregnancies characterized by placental insufficiency and impaired nutrient transport [10-11]. 
Our group recently reported increased mitochondrial DNA (mtDNA) levels in placentas of obese 
compared to normal-weight women [12]. 
Interestingly, alterations in mt function have been demonstrated to cause an excess of cellular iron 
deposition leading to hepcidin over-expression and further OxS-enhancing mechanism [13]. Hepcidin 
(Hpn) is an acute phase protein and inflammation positive regulator, also involved in iron homeostasis. 
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Its bioavailability is modulated by several systemic stimuli such as inflammation, anemia and iron 
concentration [14-15]. 
Here we quantified mtDNA in the obese maternal circulation, as a possible expression of OxS increase 
due to the high lipids overload. Moreover, in order to characterize the systemic low-grade 
inflammation, typical of both pregnancy and obesity, we measured hepcidin levels in maternal plasma. 
We also evaluated whether fetal sex was associated with different maternal levels of both biomarkers. 
 
 
MATERIAL and METHODS 
1. Population 
This is an analytic study on a cohort of pregnant women undergoing regular antenatal visits in the 
Mother and Child Department of “Luigi Sacco” Hospital, Milano. The study protocol was approved by 
the hospital Ethical Committee and all enrolled women signed an informed consent. 
Only patients with singleton spontaneous pregnancies delivering by elective Cesarean Section (CS) at 
term were included. Forty-one women were enrolled according to their pre-gestational Body Mass 
Index (BMI): 16 Normal-Weight [NW] (control group) [18≤ BMI< 25 kg/m2], 15 Normoglycemic Obese 
[OB/GDM(-)] and 10 Obese women with Gestational Diabetes Mellitus [OB/GDM(+)] [BMI ≥30 kg/m2]. 
All pregnant women had Caucasian origin. Exclusion criteria were: maternal-fetal infections, maternal 
drug-alcohol abuse, fetal abnormal karyotype-malformations, preeclampsia and intrauterine growth 
restriction. 
All patients were given specific nutritional advice and recommendations on weight gain during 
pregnancy depending on pre-gestational BMI according to our clinical protocol. 
GDM was diagnosed at 24-28 weeks of gestation by 75g oral glucose tolerance test (OGTT) [16]. GDM 
patients underwent several checks of glycemia and were given lifestyle guidelines and specific dietary 
indications, according to our clinical protocol, in order to maintain normal glycemia. No patient 
needed insulin therapy. 
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In the normal-weight group, fetuses had normal intrauterine growth and appropriate-for-gestational-
age birth weight according to reference ranges for the Italian population [17]. GDM was an exclusion 
criteria for this group.  
In all studied woman, indications for elective CS before labor were breech presentation, previous CS 
or maternal indications not related to fetal growth. 
 
Data collection 
We recorded maternal data (age, pre-gestational BMI, gestational weight gain), gestational age and 
fetal weight. Placental weight was measured after maternal the membranes trimming and umbilical 
cord removing, as previously described [3]. 
Maternal hemoglobin and hematocrit were measured at 34-36 weeks. 
Maternal fasting glycemia was obtained from the first value of the OGTT performed between 24-28 
weeks. 
 
2. Sample Collection and Processing 
Maternal blood sampling for mtDNA and hepcidin 
Maternal venous blood was collected from a radial vein into EDTA tubes prior to CS. A whole-blood 
aliquot was set aside, the remaining blood centrifuged at 1500 rpm 15 minutes at room temperature 
to obtain plasma. Samples were stored at -80°C. 
 
mtDNA Content 
Total DNA was isolated from maternal venous blood samples using QIAamp DNA Blood Mini-Kit 
(Qiagen; Valencia, CA, USA) and its concentration measured by NanoDrop-ND-1000 
spectrophotometer (Wilmington, DE, USA). 
mtDNA content was assessed by Real-time PCR, normalizing levels of a mitochondrial gene 
(Cytochrome-B) to those of a single-copy nuclear gene (RNase-P) [2-ΔCq; ΔCq = Cytochrome-B – Rnase-
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P average Cq values]. 30 ng of total DNA were analyzed in triplicate with TaqMan assays (MT-CYB: 
Hs02596867_s1 and RNase P: 4316844) by 7500 Fast Real-Time PCR (ThermoFisher-Scientific; 
Carlsbad, CA, USA); Cq values with standard deviation exceeding 0.25 were excluded and experiments 
repeated. 
 
Hepcidin 
Hepcidin (Hpn-25) concentration was measured in maternal venous plasma by solid-phase ELISA 
based on the principle of competitive binding (EIA-4705_DRG-Diagnostics; Marburg, Germany), 
according to manufacturer’s instructions. Plasma samples were diluted 1:2, analyzed in duplicate; the 
measurement interval was [2.90-12.95 ng/mL]. Hpn-25 limit of detection was 0.5 ng/mL, intra-assay 
coefficient of variation < 10%. 
 
3. Statistical Analysis 
Clinical data displayed a normal distribution (Kolmogorov-Smirnov Test) and were thus compared 
between groups by Student’s T-test, with applied correction when equality of variances assumption 
was violated (Levene’s test). 
Molecular data were un-normally distributed (Kolmogorov-Smirnov Test) and thus analyzed by Mann-
Withney U test. 
One-way between-groups multivariate analysis of variance (MANOVA) was performed once 
preliminary assumptions testing noted no serious statistical violations. Maternal pre-gestational BMI 
and hepcidin were the dependent variables, while anemia status the categorical. 
Chi-Square analyses were performed to compare anemia frequencies among groups, using Yates 
Continuity Correction. 
Correlation between values was analyzed using bivariate Pearson Correlation. 
Statistical significance was defined when p<0.05. 
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Statistical tests were performed using statistical package SPSS (IBM-Statistics, version 24.00, Armonk, 
NY, USA). 
 
 
RESULTS 
1. Characteristics of the Study Population 
Maternal, fetal and placental data of the three analyzed groups are reported in Table 1. According to 
the study design, pre-gestational BMI was significantly higher in the two obese groups than in normal-
weight, with no significant differences between obese subjects. Obese women gained on average less 
weight during pregnancy compared to normal-weight women. Maternal fasting glycemia was 
significantly higher in OB/GDM(+) compared to both NW and OB/GDM(-), in agreement with the study 
inclusion criteria. 
OB/GDM(-) presented significantly lower hemoglobin levels (Hb, 10.70 ± 1.34 g/dL) compared to 
normal-weight (11.6 ± 1.17 g/dL; p=0.05). Anemia (Hb< 11.0 g/dL) frequency was higher in OB/GDM(+) 
(40%), and resulted two-fold higher (53%) in OB/GDM(-) than in NW (25%) subjects. 
Gestational age, fetal weight and placental parameters did not differ between obese and normal-
weight women, while in OB/GDM(+) placental weight was significantly higher and placental efficiency 
significantly lower compared to both NW and to OB/GDM(-). 
The percentage of male and female neonates did not differ in obese and normal-weight groups. 
 
2. mtDNA Content in Maternal Blood 
mtDNA content was measured in maternal venous blood. In the statistical analyses three outlier 
samples from the control and one from the OB/GDM(+) group were removed. 
Figure 1 presents mtDNA in maternal venous blood of the three study groups. Maternal mtDNA was 
significantly higher in OB/GDM(-) (68.42 ± 22.37) compared to NW (52.21 ± 14.43, p= 0.05) [Figure 
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1A]. In normoglycemic women (both NW and OB) mtDNA content significantly correlated with pre-
gestational BMI (r=0.48, p=0.01) [Figure 1B]. 
mtDNA content in OB/GDM(+) (53.38 ± 5.22) was not significantly different compared to NW. 
 
3. Hepcidin Levels in Maternal Plasma 
Hpn levels in maternal venous plasma were significantly higher in OB/GDM(-) subjects (8.02 ± 3.28 
ng/mL) compared to NW (4.67 ± 1.64 ng/mL, p= 0.05) [Figure 2A]. Maternal Hpn levels did not differ 
between OB/GDM(+) (4.93 ± 2.01 ng/mL) and NW women.  
In normoglycemic women (both NW and OB) hepcidin significantly correlated with pre-gestational 
BMI (r=0.51, p=0.02) [Figure 2B]. This correlation was independent from level of Hb tested by 
MANOVA [F (2,18) = 2.78, p= 0.089; Wilks' Lambda = 0.76; partial eta squared = 0.24). 
 
mtDNA Content and Hepcidin according to Fetal Gender 
Independently from BMI categories, mothers bearing female (F) fetuses showed significantly 
increased levels of both mtDNA (67.12 ± 18.95) and maternal hepcidin (6.88 ± 2.96 ng/mL) compared 
to male (M) (49.04 ± 10.96, p=0.001; 3.95 ± 0.89 ng/mL, p=0.002 respectively) [data not shown]. 
In the normal-weight population of physiological pregnancies, mothers bearing female (F) fetuses 
presented significantly higher mtDNA levels compared to males’ (M) (F: 61.61 ± 15.15; M: 45.15 ± 
9.48, p= 0.03) [Figure 3]. Similarly, when analyzed independently from GDM association, obese 
female-mothers showed significantly higher (69.33 ± 20.32) circulating mtDNA than male (53.48 ± 
11.50, p=0.03). These differences did not reach statistical significance considering the two obese group 
separately [data not shown]. 
 
 
DISCUSSION 
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Despite worldwide increasing attention to the adverse pregnancy outcomes related to obesity, further 
data are needed to deeply understand molecular aspects related to its inflammatory/oxidative stress 
environment. 
This study focuses on the evaluation of markers of OxS (mitochondrial DNA) and inflammation 
(Hepcidin- Hpn) in the systemic circulation of healthy normal-weight and obese mothers at elective 
cesarean section. 
We found increased mitochondrial DNA levels in obese women compared to normal-weight. mtDNA 
is esteemed as a measure of mitochondrial content [10]. We previously reported that mtDNA in the 
maternal circulation is significantly higher in pregnancies affected by fetal growth restriction [11] that 
also present higher placental mtDNA [10,18]. Also in obese women we have recently found increased 
placental mtDNA [12], suggesting that increased maternal mtDNA is likely the result of the release of 
placental cell debris in the maternal circulation [19]. 
Obesity is a condition characterized by mild chronic inflammation and OxS [1]. At the same time, 
mitochondria can be critically involved in this setting since their regulation and biogenesis are 
influenced by several endocrine and nutritional stimuli as well as specific stress and hypoxia pathways 
[20-21]. The positive correlation between mtDNA and maternal hemoglobin confirmed mtDNA as a 
sensitive indicator of oxygen imbalances [10]. 
Moreover, in vitro and ex vivo studies recently reported both increased ROS production by obese 
mitochondria and impaired mitochondrial metabolism [13,20-21]. This suggests that the increase in 
mtDNA content we found in obese patients can be an adaptive mechanism to the impaired 
environment occurring in obese pregnancies. The positive correlation linking mtDNA with maternal 
BMI in OB/GDM(-) pregnancies supports this hypothesis. 
In our study population, also maternal plasma hepcidin was significantly higher in OB/GDM(-) than in 
normal-weight women. Two other studies have previously reported higher maternal hepcidin levels 
in obese women [22-23]. Indeed, obesity-related inflammation may induce hepcidin biosynthesis with 
a consequent reduction of iron supply [15]. Garcia-Valdes et al. hypothesized that Hpn can be a 
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regulatory factor leading to higher risk of iron deficiency in obese pregnant women [23]. Iron 
deficiency can also be the result of a low-quality diet that often characterizes obese patients, possibly 
leading to placental impairment and pregnancy pathologies [7-9,24]. In our population, OB/GDM(-) 
subjects presented significantly lower hemoglobin concentration, compared to normal-weight 
pregnancies, confirming these associations. Nonetheless, anemia was not related to the increase in 
hepcidin, while this was positively associated with maternal BMI. 
Recently, a cause-effect relationship involving mitochondria and hepcidin has been reported in vitro 
proposing that mitochondrial alterations, caused by excessive OxS, lead to too much cellular iron 
deposition and consequently to hepcidin over-expression, and that conversely this increased Hpn 
levels may result in disturbance of mt function [13]. The concordance between circulating mtDNA and 
hepcidin levels we found in our study population supports this hypothesis. 
 
Obese Pregnancies with GDM 
When analyzing obese groups, we found that women with Gestational Diabetes Mellitus (GDM) 
presented a different trend compared to obese without GDM. GDM is characterized by systemic 
insulin resistance and has been associated with impaired placental features [6]. Consistent with 
previous data [3], in our study OB/GDM(+) presented significantly higher placental weight and lower 
placental efficiency than both OB/GDM(-) and NW. 
Insulin resistance has been associated with inadequate hepcidin levels in diabetes [25]. This suggests 
that the presence of insulin resistance might drive Hpn biogenesis towards an opposite direction than 
the inflammation stimuli. 
On the other side, metabolic status affects mitochondria. Several studies analyzed mt dysfunctions in 
the context of obesity and glucose intolerance, both in humans and in animals [25-27]. Contrasting 
data have been reported suggesting that mitochondrial alterations are not a stable feature of insulin 
resistance in all circumstances. Nevertheless, mtDNA copy number in obese human subjects has been 
negatively related to insulin resistance [27]. Previous data also show a negative relationship between 
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insulin resistance and both hepcidin and mitochondrial levels. This suggests that when gestational 
diabetes and insulin resistance occur in obese women, an opposite driving force may act on hepcidin 
concentration and mitochondrial biogenesis, leading to the decrease in Hpn and mtDNA levels 
compared to obese normoglycemic mothers. Moreover, our clinical protocol for diabetic women 
provides habitual checks of glycemia values and specific dietary indications for glycemic control. 
Indeed, OB/GDM(+) women presented lower gestational weight gain compared to OB/GDM(-) and to 
NW, and their hemoglobin levels were similar to controls and higher compared to OB/GDM(-). This 
may occur in relation to a more balanced intake of micro/macro nutrients [28], which may also 
contribute to lower hepcidin and mtDNA levels. 
 
Sexual Dimorphism 
Here we report for the first time significantly increased levels of maternal hepcidin and circulating 
mtDNA in female- compared to male-carrying pregnancies. While Hpn differences were evident only 
comparing all the female to male mothers of the study population, statistical comparison according 
to BMI revealed significantly higher mtDNA levels in females-carrying physiological/normal-weight 
pregnancies than in males-. Indeed, in females’ mothers mtDNA was significantly higher in obese 
pregnancies compared to normal-weight, with a lack of statistical significance- probably related to the 
small sample size- when the two obese subgroups are analyzed separately. Importantly, no significant 
differences of fetal sex frequencies within the study groups were found, suggesting no involvement of 
fetal gender distribution. 
Sexual dimorphism is well recognized in placental formation and function [4]. Gonadal steroids may 
play a key role in this context. Indeed, estrogens coordinate and integrate cellular metabolism and 
mitochondrial activities by regulating mitochondrial biogenesis and function [29]. We thus might 
speculate that female placentas have higher mitochondrial content compared to males’, thus resulting 
in increased circulating mtDNA levels in the mother. 
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Another potential explanation is that placental shedding may be higher in female obese pregnancies, 
as recorded for placental metabolic pathways, morphology and efficiency in few murine/human 
models [3,30]. Indeed, sexual dimorphism is increasingly reported as a conditioning parameter in the 
intrauterine response to maternal inflammation/stress, with females more inclined to respond to 
insults [3,4]. No reports of sex-differences in inflammation markers come from recent literature. 
Hepcidin higher levels in female-carrying pregnancies may be linked to the placental fraction of Hpn 
production, but focused analyses are needed to verify this hypothesis. 
 
Limitations 
A possible limit of this study lies on the origin of mtDNA in the maternal blood in different BMI groups. 
Among blood cells, white cells, erythroblasts and platelets can contribute to the amount of measured 
mtDNA. Here, we measured mtDNA content by normalizing levels of mitochondrial Cyt-B gene to the 
nuclear RNase-P. As platelets don’t carry nuclear DNA, this might represent a possible bias in case of 
different platelets distribution within these groups. Indeed, blood cell content might be affected by 
pre-gestational BMI. However, maternal hematocrit was not different between analyzed groups, 
suggesting no differences in blood cells content and thus a not different contribution to mtDNA among 
BMI groups. 
Moreover, a larger study population would be needed to confirm possible differences in the 
mitochondrial machinery between female and male fetuses undergoing the insult of the obese 
intrauterine environment. 
 
Conclusions 
Our data provide new insight on the relation between maternal mtDNA and hepcidin and excessive 
maternal BMI or insulin resistance. This may conduce to establish new promising biomarkers and 
possible life-care intervention, ameliorating both the inflammatory and oxidative obesity-related 
milieu, aimed at reducing the obesity-related risks in pregnancy. 
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9. TABLE 
 
 
NW                                 
n= 16 
OB / GDM (-)                  
n= 15 
OB / GDM (+)                  
n= 10 
 Maternal Age [yrs] 35.4 ± 5.2 33.7 ± 6.0 35.5 ± 4.4 
 Maternal Pre-Gestational BMI [kg/m2] 21.6 ± 1.8 35.4 ± 4.8  35.6 ± 4.6  
Maternal Maternal GWG [Kg] 12.0 ± 4.1 9.5 ± 5.3 8.1 ± 5.3 
Data Maternal Venous Hemoglobin [g/dL] 11.6 ± 1.2 10.7 ± 1.3  11.3 ± 0.8 
 Maternal Venous Hematocrit [%] 34.2 ± 3.4 32.6 ± 3.5 34.0 ± 2.6 
 Maternal Fasting Glycemia [mg/dL] 78.4 ± 8.0 79.0 ± 7.3 93.9 ± 12.2  §§ 
 Gestational Age [wks] 39.1 ± 0.3 39.1 ± 0.3 39.1 ± 0.2 
Delivery Fetal Weight [g] 3420.0 ± 287.9 3320.7 ± 421.8 3371.0 ± 409.0 
Data Placental Weight [g] 460.7 ± 97.1 471.6 ± 72.7 554.0 ± 70.6  §§ 
 Placental Efficiency 7.9 ± 1.7 7.1 ± 1.1 6.1 ± 1.7  §§ 
 
 
 
Table 1: Maternal and delivery data in the study population. Data are presented as mean ± standard deviation. Comparisons were made between both 
Obese groups vs Normal Weight [p≤ 0.05, p≤ 0.01; p≤ 0.001] and between OB/GDM(+) vs OB/GDM(-) [§p≤ 0.05, §§p≤ 0.01]. NW: Normal Weight; 
OB/GDM(-): Obese without GDM; OB/GDM(+): Obese with GDM; BMI: Body Mass Index; GDM: Gestational Diabetes Mellitus; GWG: Gestational Weight Gain; 
Maternal Fasting Glycemia: referred to the first value of the OGTT; Placental Efficiency: fetal/placental weight ratio  
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10. FIGURES 
 
 
FIGURE 1 (A) and (B) 
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FIGURE 2 (A) and (B) 
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FIGURE 3 
  
22 
 
11. FIGURE CAPTIONS 
Figure 1: Maternal Blood mtDNA Content. (A) mtDNA levels in OB/GDM(-) [n= 15] and OB/GDM(+) [n= 9] vs NW [n= 14] [ p≤ 0.05] pregnant women at 
delivery. Data are shown as box plots, indicating the median and the 25th and 75th percentiles; (B): Relationship between mtDNA Content and Maternal Pre-
Gestational BMI in OB/GDM(-) [; n=15], OB/GDM(+) [; n=9] and NW [○; n=14]. Pearson Correlation data referred only to the Normoglycemic Population 
[r= +0.48, p≤ 0.01] 
 
 
Figure 2: Maternal Plasma Hepcidin. (A) Hepcidin levels in OB/GDM(-) [n= 11] and OB/GDM(+) [n= 5] vs NW [n= 10] [ p≤ 0.01] pregnant women at 
delivery. Data are shown as box plots, indicating the median and the 25th and 75th percentiles; (B): Relationship between Hepcidin Levels and Maternal Pre-
Gestational BMI in OB/GDM(-) [; n=11], OB/GDM(+) [; n=5] and NW [○; n=10]. Pearson Correlation data referred only to the Normoglycemic Population 
[r= +0.51, p≤ 0.05] 
 
 
Figure 3: Maternal Blood mtDNA Content according to Fetal Gender. Comparisons between females’ (white) or males’ (grey) mothers in Normal-Weight and 
All Obese groups [ p≤ 0.05 M vs F] 
